Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J partners with Anchor on GPCR-based therapeutics

Executive Summary

A month after closing its $10mm Series B round, Anchor Therapeutics Inc. (developing GPCR-targeting compounds) has now agreed to use its Pepducin technology to help Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. discover drug candidates for cancer and metabolic disorders.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies